SUMMARY REVIEW/ORAL MEDICINE

Data sources Medline.
Study selection Single or double blinded randomised controlled trials (RCTs), in patients suffering from orofacial pain disorders, with pain intensity as main outcome measure and antidepressants as treatment modality were included. Study quality was assessed using a 15-item checklist.
Data extraction and synthesis Two independent investigators
extracted the data and a qualitative summary was presented.
Results Six trials were included; four studies were randomised placebo-controlled trials and two were randomised active-controlled trials. All six trials were of high quality according to the 15-item criteria.
Because of the heterogeneity of treatment modalities and the low number of trials per disorder there was limited evidence to support the effectiveness of antidepressants in orofacial pain disorders.
Conclusions More randomised controlled trials are needed to come to a firm conclusion for the use of antidepressants for orofacial pain disorders. Patients suffer from co-morbid psychosocial dysfunction in chronic states. 3 Such co-morbidities along with varying symptomology and etiological factors, make treatment challenging for the clinician. Often interdisciplinary and multifactorial approaches must be implemented. Antidepressant therapies are being used to manage chronic pain dysfunctions and can also be beneficial in cases with co-morbid conditions. 4 In the orofacial region they are used without clearly defined 
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This careful checklist included an outline of selection and restriction criteria, treatment allocation, prognostic comparability, drop outs, interventions, co-interventions, blinding of patient/ therapist/observer, outcome measures, timing of measurements, side effects analysis and presentation of data. Only those studies deemed of higher quality based on a score of 50 or higher were included in the study. Though it was a very well constructed and rigorous checklist, it is unclear how the authors allocated the division of points within each category in the checklist. It is also unclear on which standard the number 50 was chosen to be the cutoff. There is only one reference made of this methodological screening tool, utilised in a 1997 study, on lower back pain interventions. 5 Six out of 142 studies methodologically qualified for inclusion in the review, with scores ranging from 52.5 to 77. Two of the studies used a cross-over design. Power of the sample sizes varied from 10-76. Mechanistically the antidepressants studied also varied; tricyclic antidepressants, serotonin selective reuptake inhibitors (SSRI), serotonin and norepinephrine reuptake inhibitors (SNRI), (SARI).
The dosage frequency for each drug varied and was not made clear in the six studies. The diagnosis also varied; BMS, AFP, bruxism, TMD and radiation induced mucositis; all having different pathogeneses and pain sequelae. Criteria for diagnosis of these conditions were not identified. TMD could have implications on intracapsular derangements or masticatory musculature. Bruxism is a parafunctional habit more than a pain syndrome. Co-morbidities were not listed nor were patients' medical histories discussed. Exclusionary criteria were not defined at all in this study. Exclusion of co-morbid conditions or other pain medications that could limit the use or effectiveness of antidepressants was not mentioned at all in any of the studies.
The authors stated in a tabulated format that pain reduction was seen in 3/6 studies. They concluded for BMS trazadone was ineffective in reducing pain in a high quality study, whereas in another study paroxetine and/or sertraline showed improvement. There is limited evidence for the effectiveness of paroxetine and sertraline and ineffectiveness of trazadone in the management of BMS. The investigators thoroughly disclosed biases in this study and could not exclude publication, reviewer and language biases. There may be additional studies that were not included due to the limited search strategies, using only Pubmed, limiting to two languages and reviewer bias, as they weren't blinded. They hoped to minimise this by using the 15-point checklist. It should also be noted that the authors disclosed no competing interests or funding and did not require approval from an ethical review board.
The results of this study are not enough to negate or promote the use of antidepressants in orofacial pain. No meta-analysis was conducted and so no real clinical conclusion can be reached based on variable studies in reference to all accounted biases. The need for RCTs with homogeneous studies with specific monotherapy for appropriately targeted diagnoses in orofacial pain is evident based on the search conducted by these authors. A narrower search of RCTs with clearly defined inclusion and exclusion criteria for one specific diagnosis in orofacial pain is recommended for more conclusive and comparable data analysis.
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